The estimated Net Worth of Daniel Barber is at least $2.15 Milion dollars as of 8 June 2022. Mr. Barber owns over 91,743 units of Aquestive Therapeutics Inc stock worth over $958,825 and over the last 6 years he sold AQST stock worth over $0. In addition, he makes $1,195,230 as Chief Operating Officer a Senior Vice President at Aquestive Therapeutics Inc.
Sign up
Mr. Barber AQST stock SEC Form 4 insiders trading
Daniel has made over 3 trades of the Aquestive Therapeutics Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he bought 91,743 units of AQST stock worth $88,073 on 8 June 2022.
The largest trade he's ever made was buying 91,743 units of Aquestive Therapeutics Inc stock on 8 June 2022 worth over $88,073. On average, Daniel trades about 6,316 units every 85 days since 2018. As of 8 June 2022 he still owns at least 193,702 units of Aquestive Therapeutics Inc stock.
You can see the complete history of Mr. Barber stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Daniel Barber biography
Daniel Barber serves as Chief Operating Officer, Senior Vice President of the Company. Mr. Barber joined our team in July 2007 and has been our Chief Operating Officer since May 2019. He has led our Strategy and Development functions since April 2014. Prior to joining our team, Mr. Barber held various positions with Quest Diagnostics in its corporate planning and international divisions. In 2010, Mr. Barber had executive oversight of our launch activities for our first two FDA approved products. Beginning in 2013, Mr. Barber helped lead our effort to develop an internal pipeline of proprietary assets. Since that time, he has had executive responsibility for our pipeline and partnership activities. Mr. Barber received his B.A. from State University of New York at Geneseo and an M.B.A from Seton Hall University.
What is the salary of Daniel Barber?
As the Chief Operating Officer a Senior Vice President of Aquestive Therapeutics Inc, the total compensation of Daniel Barber at Aquestive Therapeutics Inc is $1,195,230. There are 2 executives at Aquestive Therapeutics Inc getting paid more, with A. Mark Schobel having the highest compensation of $7,575,660.
How old is Daniel Barber?
Daniel Barber is 44, he's been the Chief Operating Officer a Senior Vice President of Aquestive Therapeutics Inc since 2019. There are 22 older and no younger executives at Aquestive Therapeutics Inc. The oldest executive at Aquestive Therapeutics Inc is Gregory Brown, 66, who is the Independent Director.
What's Daniel Barber's mailing address?
Daniel's mailing address filed with the SEC is C/O AQUESTIVE THERAPEUTICS, INC., 30 TECHNOLOGY DRIVE, WARREN, NJ, 07059.
Insiders trading at Aquestive Therapeutics Inc
Over the last 6 years, insiders at Aquestive Therapeutics Inc have traded over $1,898,648 worth of Aquestive Therapeutics Inc stock and bought 370,463 units worth $3,088,399 . The most active insiders traders include Marco Taglietti, Nancy Lurker a Alexander Mark Schobel. On average, Aquestive Therapeutics Inc executives and independent directors trade stock every 36 days with the average trade being worth of $77,928. The most recent stock trade was executed by Alexander Mark Schobel on 15 March 2024, trading 50,000 units of AQST stock currently worth $300,000.
What does Aquestive Therapeutics Inc do?
aquestive therapeutics is a specialty pharmaceutical company that advances and commercializes medicines to solve critical healthcare problems and meaningfully improve people’s lives. our team asks questions and identifies issues others have not, and builds solutions that empower patients and their caregivers with better ways to manage complex diseases. our initial focus, supported by our current approved products and late stage pipeline, is to address immediate cns challenges.
What does Aquestive Therapeutics Inc's logo look like?
Complete history of Mr. Barber stock trades at Aquestive Therapeutics Inc
Aquestive Therapeutics Inc executives and stock owners
Aquestive Therapeutics Inc executives and other stock owners filed with the SEC include:
-
A. Mark Schobel,
Chief Innovation and Technology Officer -
Keith Kendall,
President, Chief Executive Officer, Director -
Daniel Barber,
Chief Operating Officer, Senior Vice President -
John Maxwell,
Senior Vice President, Chief Financial Officer -
Keith J. Kendall,
CEO, Pres & Director -
Daniel Barber,
Sr. VP & COO -
Santo Costa,
Independent Chairman of the Board -
James Scibetta,
Independent Director -
Douglas Bratton,
Independent Director -
Nancy Lurker,
Independent Director -
Gregory Brown,
Independent Director -
John Cochran,
Vice Chairman of the Board -
Gary Slatko,
Senior Vice President, Chief Medical Officer -
Kenneth Marshall,
Senior Vice President - Chief Commercial Officer -
Peter Boyd,
Senior Vice President - Business Process and Information Technology -
Theresa Wood,
Senior Vice President - Human Resources and Organizational Development -
Lori Braender,
Senior Vice President - General Counsel, Chief Compliance Officer and Corporate Secretary -
Dr. Gary H. Slatko M.D., MBA,
Sr. VP & Chief Medical Officer -
Kenneth W. Marshall,
Sr. VP & Chief Commercial Officer -
Peter E. Boyd,
Sr. VP of Bus. Process & Information Technology -
Dr. Eric Dadey Ph.D.,
Sr. Vice-Pres of R&D -
Theresa Wood,
Sr. VP of HR & Organizational Devel. -
Lori J. Braender Esq.,
Sr. VP, Gen. Counsel, Chief Compliance Officer & Corp. Sec. -
Alexander Mark Schobel,
Chief Innovation & Technology Officer -
A. Ernest Toth Jr.,
Sr. VP & CFO -
Timothy E Morris,
-
Ken W. Marshall,
SVP, Chief Commercial Officer -
Marco Taglietti,
-
Julie Krop,
-
Douglas K Monoline Partners...,
-
Cassie Jung,
SVP, Operations -
Douglas K Mono Line Partner...,
-
Kenneth Truitt,
Chief Medical Officer -
A Ernest Jr Toth,
SVP, Chief Financial Officer -
Carl N Kraus,
Chief Medical Officer -
Stephen Wargacki,
Chief Science Officer -
Abigail L. Jenkins,
-
Sherry Korczynski,
SVP Sales and Marketing